L
Linda Wietecha
Researcher at Eli Lilly and Company
Publications - 24
Citations - 764
Linda Wietecha is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Atomoxetine & Attention deficit hyperactivity disorder. The author has an hindex of 12, co-authored 19 publications receiving 551 citations.
Papers
More filters
Journal ArticleDOI
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.
Bernice Kuca,Stephen D. Silberstein,Linda Wietecha,Paul Berg,Gregory Dozier,Richard B. Lipton +5 more
TL;DR: This study provides Class I evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.
Journal ArticleDOI
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Peter J. Goadsby,Linda Wietecha,Ellen B. Dennehy,Ellen B. Dennehy,Bernice Kuca,Michael Case,Sheena K. Aurora,Charly Gaul +7 more
TL;DR: The Goadsby et al. study shows that lasmiditan is efficacious and relatively well tolerated in the acute treatment of migraine in adults, including those with cardiovascular risk factors or a prior history of cardiovascular events.
Journal ArticleDOI
Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial.
TL;DR: Atomoxetine demonstrated significant improvement in ADHD symptoms at 12 and 24 weeks over PBO, and adverse events overall and for on-label or slow titration to ATX were similar and consistent with previous adult ATX studies.
Posted ContentDOI
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
Meghan N. Dougan,M Azizad,P. Chen,Becca Feldman,Matthew B. Frieman,A. Igbinadolor,P. R. Kumar,Jason Morris,Jeffrey A Potts,Lauren Baracco,Lee Macpherson,Nicole L. Kallewaard,Darshna Patel,Matthew M. Hufford,Linda Wietecha,Emmanuel Chigutsa,Sarah Demmon,Britta E. Jones,Ajay Nirula,Daniel Skovronsky,M. Williams,Robert L. Gottlieb +21 more
TL;DR: Safety results were consistent with previous studies investigating mAbs targeting SARS-CoV-2, and patients at high risk for progression to severe COVID-19 received only active therapy without placebo.
Journal ArticleDOI
Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
Linda Wietecha,David Wynne Williams,Sally E. Shaywitz,Bennett A. Shaywitz,Stephen R. Hooper,Sharon B. Wigal,David W. Dunn,Keith McBurnett +7 more
TL;DR: In this paper, the authors evaluated atomoxetine treatment effects in attention-deficit/hyperactivity disorder (ADHD) only, ADHD+D, or dyslexia only on ADHD core symptoms and on sluggish cognitive tempo, working memory, life performance and self-concept.